Blood Grouping Reagents Market by End-users and Geography - Forecast and Analysis 2020-2024

世界の血液型試薬市場予測・分析2020-2024

◆タイトル:Blood Grouping Reagents Market by End-users and Geography - Forecast and Analysis 2020-2024
◆商品コード:IRTNTR40141
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年11月
◆ページ数:141
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートは血液型試薬の世界市場について調査・分析し、エグゼクティブサマリー、レポートの範囲、市場状況、市場規模、ファイブフォース分析、エンドユーザー別(病院及び血液銀行、臨床検査室、学術研究機関)分析、顧客状況、地域別状況、意思決定フレームワーク、市場の要因と課題、市場動向、企業状況、企業分析などを含め、次の構成でお届けいたします。
・エグゼクティブサマリー
・レポートの範囲
・市場状況
・市場規模
・ファイブフォース分析
・血液型試薬の世界市場:エンドユーザー別(病院及び血液銀行、臨床検査室、学術研究機関)
・顧客状況
・地域別状況
・意思決定フレームワーク
・市場の要因と課題
・市場動向
・企業状況
・企業分析

Global Blood-Grouping Reagents Market: About this market
Technavio’s blood-grouping reagents market analysis considers sales from hospitals and blood banks; clinical laboratories; and academic and research institute end-users. Our study also finds the sales of blood-grouping reagents in Asia, Europe, North America, and ROW. In 2019, the hospitals and blood banks segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing demand for blood transfusion and the rise in the number of hospitals and clinics will play a significant role in the hospitals and blood banks segment to maintain its market position. Also, our global blood-grouping reagents market report looks at factors such as the increasing prevalence of chronic disorders, the rise in blood donations, and growing demand for blood transfusions and blood group typing. However, the risk associated with blood transfusion, lack of skilled healthcare professionals, and stringent regulatory process for blood transfusion may hamper the growth of the blood-grouping reagents industry over the forecast period.

Global Blood-Grouping Reagents Market: Overview
Growing demand for blood transfusions and blood group typing
The demand for blood transfusions and blood grouping is growing rapidly, owing to the increase in demand for blood. The increase in demand for blood transfusions can be attributed to several types of emergency cases, including road accidents leading to loss of blood and death. Patients suffering from conditions such as hemolytic anemia, sickle cell anemia, hemophilia, thalassemia, kidney, and liver diseases also require blood transfusion often. This is driving the demand for blood grouping reagents as they are used by blood banks and hospitals for safe transfusion of blood and elimination of risks associated with infections. Thus, the growing demand for blood transfusions and blood group typing will lead to the expansion of the global blood-grouping reagents market at a CAGR of over 10% during the forecast period.

Advancement in technology
Advances in technology help in increasing the adherence of people to diagnosis, which aids in obtaining effective and quick results. Also, the advent of technologies such as molecular typing as a substitute to the traditional blood grouping method is trending. The molecular blood grouping method includes the detection of polymorphisms and mutations that control the expression of blood group antigens. Moreover, automated blood group typing products improve the quality of testing by decreasing human errors in sample identification. Also, the emergence of column agglutination technique (CAT), solid-phase red cell adherence assay (SPRCA), erythrocyte-magnetized technique (EMT), and automated microplate systems will help to improve the quality and accuracy of testing and results. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global blood-grouping reagents market during the forecast period 2020-2024, click here.

Competitive Landscape
With the presence of a few major players, the global blood-grouping reagents market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading blood-grouping reagents manufacturers, that include Bio-Rad Laboratories Inc., DIAGAST, Grifols SA, Immucor Inc., Merck KGaA, Novacyt SA, Ortho-Clinical Diagnostics Inc., Quotient Ltd., Rapid Labs Ltd., and Ybio Inc.
Also, the blood-grouping reagents market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• Value chain analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2019
• Market size and forecast 2019-2024
• Market Outlook
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY END-USER
• Market segmentation by end-user
• Comparison by end-user
• Hospitals and blood banks – Market size and forecast 2019-2024
• Clinical laboratories – Market size and forecast 2019-2024
• Academic and research institutes – Market size and forecast 2019-2024
• Market opportunity by end-user
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges s
PART 11: MARKET TRENDS
• Emergence of social media marketing
• Advancement in technology
• Increasing penetration of healthcare facilities
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bio-Rad Laboratories Inc.
• DIAGAST
• Grifols SA
• Immucor Inc.
• Merck KGaA
• Novacyt SA
• Ortho-Clinical Diagnostics Inc.
• Quotient Ltd.
• Rapid Labs Ltd.
• Ybio Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Vendors: Key offerings
Exhibit 02: Global healthcare market
Exhibit 03: Segments of global healthcare market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: End-user – Market share 2019-2024 (%)
Exhibit 19: Comparison by end-user
Exhibit 20: Hospitals and blood banks – Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Hospitals and blood banks – Year-over-year growth 2020-2024 (%)
Exhibit 22: Clinical laboratories – Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Clinical laboratories – Year-over-year growth 2020-2024 (%)
Exhibit 24: Academic and research institutes – Market size and forecast 2019-2024 ($ millions)
Exhibit 25: Academic and research institutes – Year-over-year growth 2020-2024 (%)
Exhibit 26: Market opportunity by end-user
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2019-2024 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 31: North America – Year-over-year growth 2020-2024 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 37: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 40: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Bio-Rad Laboratories Inc. – Vendor overview
Exhibit 51: Bio-Rad Laboratories Inc. – Product segments
Exhibit 52: Bio-Rad Laboratories Inc. – Organizational developments
Exhibit 53: Bio-Rad Laboratories Inc. – Geographic focus
Exhibit 54: Bio-Rad Laboratories Inc. – Segment focus
Exhibit 55: Bio-Rad Laboratories Inc. – Key offerings
Exhibit 56: DIAGAST – Vendor overview
Exhibit 57: DIAGAST – Business segments
Exhibit 58: DIAGAST – Key offerings
Exhibit 59: Grifols SA – Vendor overview
Exhibit 60: Grifols SA – Product segments
Exhibit 61: Grifols SA – Organizational developments
Exhibit 62: Grifols SA – Geographic focus
Exhibit 63: Grifols SA – Segment focus
Exhibit 64: Grifols SA – Key offerings
Exhibit 65: Immucor Inc. – Vendor overview
Exhibit 66: Immucor Inc. – Business segments
Exhibit 67: Immucor Inc. – Organizational developments
Exhibit 68: Immucor Inc. – Key offerings
Exhibit 69: Merck KGaA – Vendor overview
Exhibit 70: Merck KGaA – Business segments
Exhibit 71: Merck KGaA – Organizational developments
Exhibit 72: Merck KGaA – Geographic focus
Exhibit 73: Merck KGaA – Segment focus
Exhibit 74: Merck KGaA – Key offerings
Exhibit 75: Novacyt SA – Vendor overview
Exhibit 76: Novacyt SA – Business segments
Exhibit 77: Novacyt SA – Organizational developments
Exhibit 78: Novacyt SA – Geographic focus
Exhibit 79: Novacyt SA – Segment focus
Exhibit 80: Novacyt SA – Key offerings
Exhibit 81: Ortho-Clinical Diagnostics Inc. – Vendor overview
Exhibit 82: Ortho-Clinical Diagnostics Inc. – Business segments
Exhibit 83: Ortho-Clinical Diagnostics Inc. – Key offerings
Exhibit 84: Quotient Ltd. – Vendor overview
Exhibit 85: Quotient Ltd. – Business segments
Exhibit 86: Quotient Ltd. – Geographic focus
Exhibit 87: Quotient Ltd. – Key offerings
Exhibit 88: Rapid Labs Ltd. – Vendor overview
Exhibit 89: Rapid Labs Ltd. – Product segments
Exhibit 90: Rapid Labs Ltd. – Key offerings
Exhibit 91: Ybio Inc. – Vendor overview
Exhibit 92: Ybio Inc. – Product segments
Exhibit 93: Ybio Inc. – Key offerings
Exhibit 94: Validation techniques employed for market sizing
Exhibit 95: Definition of market positioning of vendors



【掲載企業】

Bio-Rad Laboratories Inc., DIAGAST, Grifols SA, Immucor Inc., Merck KGaA, Novacyt SA, Ortho-Clinical Diagnostics Inc., Quotient Ltd., Rapid Labs Ltd., and Ybio Inc.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[世界の血液型試薬市場予測・分析2020-2024]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆